The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a rapid diagnostic method for identifying patients that will benefit from Chimeric Antigen Receptor (CAR) T cell therapy. Chimeric Antigen Receptor T cell therapy is an emerging clinical method of producing lasting remission in cancer patients by re engineering patient’s own T cells. The therapy also remains under active investigation for other emerging applications. The T cells in nearly half of cancer patients eligible for CAR T cell therapy are not sufficiently healthy to be successfully manufactured into viable and effective CAR T cells for use as intended. This leads to CAR T cell manufacturing failures for 15-69% of patients, resulting in a significant burden to the health care system with an estimated cost of $375k per patient along with increased risks to patient morbidity and severe adverse events. The system aims to be the first to correlate specific quantifiable energy measures with CAR T cell manufacturing failure risks. If successful this new screening method would provide a high throughput system capable of identifying patients at high risk for CAR T cell manufacturing failure with reduced time, labor for optimization and reagent validation than current methods. This would allow patients to pursue other clinical options sooner rather than undergoing ineffective CAR T therapy thereby enabling them to see alternative viable options sonner while reducing unn